Ayad K. Ali, RPh, PhD, FACE

Principal Pharmacoepidemiologist
Eli Lilly and Company

Poster(s):

• (207) Disproportionality Analysis for Post-Manufacturing Change Safety Monitoring of Biologics: Example of Insulin Lispro
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST

• (13) Effectiveness of Risk Minimization Plan for Concentrated Insulin Lispro in France, Germany and Sweden
  Friday, August 26, 2022

  8:00 AM – 6:00 PM CEST

• (323) Lot-Specific Monitoring of Insulin Lispro Safety Following Changes in The Purification Process
  Saturday, August 27, 2022

  8:00 AM – 6:00 PM CEST

• (208) Overview of Biases Affecting the Interpretation of Signals Identified in Drug Safety Surveillance Systems
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST